The U.S. FDA Center for Drug Evaluation and Research (CDER) announced the new CDER Center for Real-World Evidence Innovation (CCRI) which aims to coordinate, advance, and promote the use of real-world data (RWD) and real-world evidence (RWE) in regulatory decision-making across CDER.
RWD relates to a patient’s health status and/or the delivery of health care routinely collected from a variety of sources (e.g., electronic health records, medical claims, product and disease registries, and cutting-edge technologies). By using data from routine clinical practice, we can generate evidence (referred to as RWE) that provides valuable insights into the safety and effectiveness of medical products.
The volume and complexity of data available to support drug development have increased substantially over the past several decades. This increase—combined with enhanced computing power, emerging technologies, and advances in epidemiological and statistical methods—are transforming how drugs are developed, manufactured, and utilized.
The goal of CCRI will be to advance, coordinate, and promote consistency across RWD/RWE-related initiatives in CDER, including related uses of emerging technologies in both internal and external FDA activities. We envision CCRI as a collaborative core for innovation and a focal point to ensure CDER promotes consistency and transparency on topics related to RWD and RWE.
With the upcoming retirement of Dr. John Concato, who has successfully led the development of CDER’s RWE program for the past four years, the FDA has launched a national search for a new leader of CCRI, who will be supported by a team of leaders and experts from offices already conducting activities under the CDER RWE Program.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!